BMS-945429

BIOLOGICAL3 trials

Sponsors

CSL Behring

Conditions

Arthritis, PsoriaticCrohn's DiseaseRheumatoid Arthritis

Phase 2

Phase IIB Rheumatoid Arthritis Dose Ranging Study for BMS-945429 in Subjects Who Are Not Responding to Methotrexate

CompletedNCT01373151

CSL BehringRheumatoid Arthritis

Start: 2011-06-30End: 2015-06-30Updated: 2021-12-06

Psoriatic Arthritis Dose Ranging Study for BMS-945429 in Subjects Who Are Not Responding to NSAIDs or Non-biologic Disease Modifying Anti-rheumatic Drugs (DMARDs) Therapy

CompletedNCT01490450

CSL BehringArthritis, Psoriatic

Start: 2011-12-31End: 2015-06-30Updated: 2021-11-05

Dose Ranging Study of BMS-945429 in Subjects With Moderate to Severe Crohn's Disease

TerminatedNCT01545050

CSL BehringCrohn's Disease

Start: 2012-06-30End: 2013-12-31Updated: 2021-12-03

Related Papers

The Efficacy and Safety of Clazakizumab, an Anti-Interleukin-6 Monoclonal Antibody, in a Phase IIb Study of Adults With Active Psoriatic Arthritis.

2016-09-01115 citations